CJC-1295: Peptide Profile, CAS & Properties
CAS 863288-34-0 · 3367.9 g/mol
CJC-1295 (CAS 863288-34-0) is a synthetic, modified growth-hormone-releasing-hormone (GHRH) analogue based on the GHRH(1-29) backbone, also known as CJC-1295 without DAC or Modified GRF 1-29. It is not approved by the FDA, EMA or other major regulators and is prohibited under WADA. This page provides reference information on CJC-1295.
- CAS Number
- 863288-34-0
- Molecular Formula
- C152H252N44O42
- Molecular Weight
- 3367.9 g/mol
- Drug Class
- GHRH analogue
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), built on the GHRH(1-29) backbone with four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27) intended to resist enzymatic degradation. Under CAS 863288-34-0 this is the form known as CJC-1295 without DAC (also called Modified GRF 1-29): it is a 29-residue peptide amide and does not carry the maleimidopropionyl 'drug affinity complex' (DAC) albumin-binding modification, so it is shorter-acting than the separate DAC-conjugated variant. Mechanistically, GHRH analogues act on GHRH receptors of the anterior pituitary to influence growth-hormone signalling; this is described here as a factual mechanism, not a therapeutic claim.
Chemically, CJC-1295 (CAS 863288-34-0, molecular formula C152H252N44O42, ~3367.9 g/mol) is a 29-amino-acid modified GHRH(1-29) analogue typically encountered as a lyophilised powder. CJC-1295 is not approved by the FDA, EMA or other major regulators for therapeutic use; clinical development of the compound was discontinued and it is prohibited under the World Anti-Doping Agency code.
How CJC-1295 Is Produced & Characterised
CJC-1295 is a synthetically demanding peptide: the 29-mer length, the D-amino-acid substitution at position 2 and multiple non-native residues all create opportunities for deletion sequences, diastereomers and epimerisation that must be tightly controlled. As a reference point for this class, modified GHRH analogues of this type are generally prepared by optimised Fmoc solid-phase peptide synthesis (SPPS), then purified on preparative dynamic axial compression (DAC) HPLC columns to isolate the target sequence sharply from closely related impurities, and lyophilised to a stable, uniform powder.
Analytical characterisation for peptides of this complexity typically combines UPLC/HPLC purity determination with LC-MS to confirm the intended sequence and resolve minor structural variants, alongside measurement of water content, acetate/counter-ion content, residual solvents and peptide content. These approaches are described here as general industry and reference-method information for the peptide class, not as the activity of any single producer.
Typical Quality Specifications
Reference-grade and research-grade peptides in this class are commonly released against a defined specification documented in a Certificate of Analysis (COA). Purity is determined by UPLC/HPLC and the sequence and minor structural variants are confirmed by LC-MS impurity profiling. Typical high-grade material is specified at ≥99.0% purity, with individual impurities controlled below 0.10%, and may be supported by ICH Q1A(R2) long-term and accelerated stability data.
Additional parameters that are typically characterised for a peptide of this type include water content, acetate/counter-ion content, residual solvents and peptide content. Analytical methods used for such characterisation are commonly validated to ICH Q2(R1). These are presented as typical specification parameters for reference purposes.
Regulatory Status & Context
CJC-1295 is not approved by the FDA, EMA or other major regulators for therapeutic use. Its clinical development was discontinued, and it has no marketing authorisation as a finished medicinal product. The compound is prohibited under the World Anti-Doping Agency (WADA) code.
Because CJC-1295 has no approved therapeutic indication, it is encountered only in research and reference-standard contexts. No efficacy or therapeutic-benefit claims are associated with the molecule, and this page presents its chemistry, classification and regulatory status as factual reference information.
CJC-1295 API — Specifications
| CAS Number | 863288-34-0 |
|---|---|
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3367.9 g/mol |
| Sequence | 29-amino-acid modified GHRH(1-29) analogue (CJC-1295 without DAC / Mod GRF 1-29) |
| Drug Class | GHRH analogue |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Form | Lyophilised powder |
| Regulatory Status | Not FDA/EMA approved; WADA-prohibited; research use only |
| Storage | Store at -20°C, protected from light & moisture |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Not approved by the FDA, EMA or other major regulators for therapeutic use. Clinical development was discontinued and the compound is prohibited under WADA. Handled only as a research / reference-standard material.
CJC-1295 API — Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), built on the GHRH(1-29) backbone with four amino-acid substitutions intended to resist enzymatic degradation. The form under CAS 863288-34-0 is known as CJC-1295 without DAC (Modified GRF 1-29), a 29-residue peptide amide that does not carry the DAC albumin-binding modification of the separate DAC-conjugated variant.
What is the CAS number and molecular weight of CJC-1295?
CJC-1295's CAS number is 863288-34-0, its molecular formula is C152H252N44O42, and its molecular weight is approximately 3367.9 g/mol. This CAS identifies the CJC-1295 without DAC (Modified GRF 1-29) form — a 29-amino-acid modified GHRH(1-29) analogue, typically a lyophilised peptide amide.
Is CJC-1295 approved?
No. CJC-1295 is not approved by the FDA, EMA or other major regulators for therapeutic use. Its clinical development was discontinued and it is prohibited under the World Anti-Doping Agency code. It is encountered only for research and reference-standard purposes, with no efficacy or therapeutic-benefit claims.
What class of peptide is CJC-1295?
CJC-1295 is a GHRH analogue — a synthetic peptide modelled on growth-hormone-releasing hormone. It falls within the growth and metabolism class of peptides. Mechanistically, GHRH analogues act on GHRH receptors of the anterior pituitary to influence growth-hormone signalling; this is stated as factual chemistry rather than a therapeutic indication.
What is CJC-1295 studied for?
CJC-1295 has been examined in research contexts as a GHRH analogue relevant to growth-hormone modulation. It has no approved therapeutic use; its clinical development was discontinued and it remains prohibited under the WADA code. Any references to it are limited to research and reference-standard work.
How is a peptide like CJC-1295 produced?
Modified GHRH analogues of this type are generally produced by optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling and epimerisation control across the 29-mer, followed by preparative dynamic axial compression (DAC) HPLC purification and lyophilisation to a stable powder. This is general reference information for the peptide class.
Related Peptide APIs
Sermorelin API
CAS 86168-78-7
Growth & MetabolismTesamorelin API
CAS 218949-48-5
Growth & MetabolismAOD-9604 API
CAS 221231-10-3
GLP-1 & Incretin Multi-AgonistsSemaglutide API
CAS 910463-68-2
Technical Reference Page
WinHyCare neither supplies nor manufactures CJC-1295; this page is provided as a technical reference. The peptide API we supply is Semaglutide.